newsfilter
← Latest News
GlobeNewswire·

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome